InvestorsObserver
×
News Home

Is Ampio Pharmaceuticals Inc (AMPE) the Top Pick in the Biotechnology Industry?

Tuesday, January 19, 2021 02:10 PM | InvestorsObserver Analysts

Mentioned in this article

Is Ampio Pharmaceuticals Inc (AMPE) the Top Pick in the Biotechnology Industry?

Ampio Pharmaceuticals Inc (AMPE) is near the top in its industry group according to InvestorsObserver. AMPE gets an overall rating of 63. That means it scores higher than 63 percent of stocks. Ampio Pharmaceuticals Inc gets a 77 rank in the Biotechnology industry. Biotechnology is number 36 out of 148 industries.

Overall Score - 63
AMPE has an Overall Score of 63. Find out what this means to you and get the rest of the rankings on AMPE!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Ampio Pharmaceuticals Inc Stock Today?

Ampio Pharmaceuticals Inc (AMPE) stock is trading at $1.50 as of 2:05 PM on Tuesday, Jan 19, an increase of $0.15, or 11.11% from the previous closing price of $1.35. The stock has traded between $1.35 and $1.60 so far today. Volume today is low. So far 5,511,356 shares have traded compared to average volume of 10,250,925 shares.

Click Here to get the full Stock Score Report on Ampio Pharmaceuticals Inc (AMPE) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App